The Development of CEO of Innovative Drug Companies in the World's Best-selling Drug List in 2025


Release time:

2019-11-25

A few days ago, Medtronic's new drug-coated balloon IN.PACT AV was approved by the US FDA. The balloon was specially designed by Medtronic to help clear the venous access used by patients undergoing dialysis treatment.

A few days ago, Medtronic's new drug-coated balloon IN.PACT AV was approved by the US FDA. The balloon was specially designed by Medtronic to help clear the venous access used by patients undergoing dialysis treatment.

Headline bacteria: dialysis patient gospel is coming.

[clove garden Insight database] domestic first PD-L1 monoclonal antibody to be approved

On November 24, AstraZeneca's PD-L1 Durvalumab injection (Imfinzi) in the domestic market application in the "approval" status (acceptance number: JXSS1800040/JXSS1800041 ), is expected to be approved in the near future to become the first listed PD-L1 monoclonal antibody drug for the treatment of inoperable stage III non-small cell lung cancer.

Headline bacteria: AZ power.

[WuXi AppTec] For the first time in ten years, OS Tecentriq combination is better than first-line standard therapy in liver cancer patients

A few days ago, Roche (Roche) announced the PD-L1 antibody Tecentriq(atezolizumab, Atillizumab) combined with Avastin(bevacizumab, bevacizumab) combination therapy, in the treatment of unresectable hepatocellular carcinoma (HCC) patients who have not received prior systemic treatment in the IMbrave150 of the 3 phase of the trial has achieved positive results.